James Mulshine to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications James Mulshine has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.366
-
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005 May 15; 65(10):4181-90.
Score: 0.219
-
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13.
Score: 0.029
-
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
Score: 0.029
-
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994 Oct; 12(10):2022-34.
Score: 0.026
-
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81.
Score: 0.025
-
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
Score: 0.015
-
Diagnosis and significance of liver metastases in small cell carcinoma of the lung. J Clin Oncol. 1984 Jul; 2(7):733-41.
Score: 0.013
-
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
Score: 0.006
-
Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res. 1989 May 01; 49(9):2390-7.
Score: 0.005